| Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype L Vermunt, SAM Sikkes, A Van Den Hout, R Handels, I Bos, ... Alzheimer's & Dementia 15 (7), 888-898, 2019 | 423 | 2019 |
| Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World … P Lewczuk, P Riederer, SE O’bryant, MM Verbeek, B Dubois, PJ Visser, ... The world journal of biological psychiatry 19 (4), 244-328, 2018 | 246 | 2018 |
| Impact of molecular imaging on the diagnostic process in a memory clinic R Ossenkoppele, ND Prins, YAL Pijnenburg, AW Lemstra, ... Alzheimer's & dementia 9 (4), 414-421, 2013 | 212 | 2013 |
| Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia AH Simonsen, SK Herukka, N Andreasen, I Baldeiras, M Bjerke, ... Alzheimer's & Dementia 13 (3), 274-284, 2017 | 163 | 2017 |
| Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment SK Herukka, AH Simonsen, N Andreasen, I Baldeiras, M Bjerke, ... Alzheimer's & Dementia 13 (3), 285-295, 2017 | 148 | 2017 |
| Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design IA Van Rossum, S Vos, R Handels, PJ Visser Journal of Alzheimer's Disease 20 (3), 881-891, 2010 | 140 | 2010 |
| Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79 (3), 228-243, 2022 | 114 | 2022 |
| Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI S Vos, I van Rossum, L Burns, D Knol, P Scheltens, H Soininen, ... Neurobiology of aging 33 (10), 2272-2281, 2012 | 103 | 2012 |
| Health economic evaluation of treatments for Alzheimer′ s disease: impact of new diagnostic criteria A Wimo, C Ballard, C Brayne, S Gauthier, R Handels, RW Jones, ... Journal of internal medicine 275 (3), 304-316, 2014 | 99 | 2014 |
| Needs and quality of life of people with middle-stage dementia and their family carers from the European Actifcare study. When informal care alone may not suffice L Kerpershoek, M de Vugt, C Wolfs, B Woods, H Jelley, M Orrell, ... Aging & mental health 22 (7), 897-902, 2018 | 93 | 2018 |
| Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic … F Landeiro, S Mughal, K Walsh, E Nye, J Morton, H Williams, I Ghinai, ... Alzheimer's research & therapy 12, 1-14, 2020 | 64 | 2020 |
| Determinants of care costs of patients with dementia or cognitive impairment RLH Handels, CAG Wolfs, P Aalten, FRJ Verhey, JL Severens Alzheimer Disease & Associated Disorders 27 (1), 30-36, 2013 | 62 | 2013 |
| Access to timely formal dementia care in Europe: protocol of the Actifcare (ACcess to Timely Formal Care) study L Kerpershoek, M de Vugt, C Wolfs, H Jelley, M Orrel, B Woods, ... BMC health services research 16, 1-7, 2016 | 61 | 2016 |
| Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework C Green, R Handels, A Gustavsson, A Wimo, B Winblad, A Sköldunger, ... Alzheimer's & Dementia 15 (10), 1309-1321, 2019 | 53 | 2019 |
| Diagnosing Alzheimer's disease: a systematic review of economic evaluations RLH Handels, CAG Wolfs, P Aalten, MA Joore, FRJ Verhey, JL Severens Alzheimer's & Dementia 10 (2), 225-237, 2014 | 50 | 2014 |
| Quality of life, care resource use, and costs of dementia in 8 European countries in a cross-sectional cohort of the actifcare study RLH Handels, A Sköldunger, A Bieber, RT Edwards, ... Journal of Alzheimer's Disease 66 (3), 1027-1040, 2018 | 41 | 2018 |
| Caregiver profiles in dementia related to quality of life, depression and perseverance time in the European Actifcare study: the importance of social health EPCJ Janssen, M de Vugt, S Köhler, C Wolfs, L Kerpershoek, ... Aging & mental health 21 (1), 49-57, 2017 | 40 | 2017 |
| Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers RLH Handels, SJB Vos, MG Kramberger, V Jelic, K Blennow, ... Alzheimer's & Dementia 13 (8), 903-912, 2017 | 39 | 2017 |
| Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study RLH Handels, P Aalten, CAG Wolfs, M OldeRikkert, P Scheltens, ... BMC neurology 12, 1-8, 2012 | 39 | 2012 |
| Quantifying and describing the natural history and costs of Alzheimer’s disease and effects of hypothetical interventions A Wimo, R Handels, B Winblad, CM Black, G Johansson, S Salomonsson, ... Journal of Alzheimer's Disease 75 (3), 891-902, 2020 | 36 | 2020 |
Linus JönssonAlzheimer's Disease Research Center, Karolinska Institutetki.se의 이메일 확인됨
